Roche’s Genentech bets on radiopharmaceuticals in partnership with PeptiDream
放射疗法并购上市批准引进/卖出临床研究
Dive Brief:
In a deeper move into radiopharmaceuticals, Roche’s Genentech unit will collaborate with the Japan-based biotechnology company PeptiDream to develop “peptide-radioisotope” conjugates, PeptiDream said Wednesday.
PeptiDream will use its peptide discovery platform system to identify and develop candidates for potential cancer drugs against targets Genentech will focus on. Under the deal, PeptiDream will receive $40 million up front and is eligible to receive up to $1 billion in milestone payments.
The new deal expands upon an initial partnership formed between the two companies in 2015, which resulted in Genentech licensing its platform system technology the following year. The deal was expanded again in 2018.
Dive Insight:
Interest in radiopharmaceuticals has been taking off ever since Novartis won drug approval of a drug it acquired with the buyout of the biotech Endocyte. Other big drugmakers such as Merck & Co. and Bristol Myers Squibb are acquiring a stake in the new space that, while enticing, still faces several obstacles through development.
Targeted radiation drugs such as Novartis’ drugs Pluvicto and Lutathera are more attractive than typical radiation therapy because the medicines can target cancer cells while sparing surrounding healthy cells. However, manufacturing and supplying radioisotopes is a long and complex process. Earlier candidates struggled to take off after development, and Novartis faced initial problems with supply.
PeptiDream has been in the radiopharma space for some time. The company, founded in 2006, said it sells and markets radiopharmaceutical products in Japan through its wholly-owned subsidiary PDRadiopharma.
Its work has caught the eye of other pharmaceutical companies and has several other partnerships under its belt including with Bristol Myers, Novartis and Astellas Pharma. San Diego-based biotech RayzeBio, which went public last week, has also partnered with PeptiDream and developed two targeted radiopharmaceuticals.
In the Genentech deal, PeptiDream will take the lead on the preclinical development of radioisotope drug conjugates. Once identified, Genentech will then take over on development and commercialization.
PeptiDream retains its right to develop and commercialize its drug conjugates in Japan.
'
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
靶点
-来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。